Table of Contents

company-logo

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals Dividend Announcement

• Catalyst Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Catalyst Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Catalyst Pharmaceuticals Dividend History

Catalyst Pharmaceuticals Dividend Yield

Catalyst Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Catalyst Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Catalyst Pharmaceuticals Financial Ratios

P/E ratio19.53
PEG ratio0.47
P/B ratio4.22
ROE25.74%
Payout ratio0.00%
Current ratio5.11
Quick ratio4.92
Cash Ratio4.20

Catalyst Pharmaceuticals Dividend FAQ

Does Catalyst Pharmaceuticals stock pay dividends?
Catalyst Pharmaceuticals does not currently pay dividends to its shareholders.
Has Catalyst Pharmaceuticals ever paid a dividend?
No, Catalyst Pharmaceuticals has no a history of paying dividends to its shareholders. Catalyst Pharmaceuticals is not known for its dividend payments.
Why doesn't Catalyst Pharmaceuticals pay dividends?
There are several potential reasons why Catalyst Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Catalyst Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Catalyst Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Catalyst Pharmaceuticals a dividend aristocrat?
Catalyst Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Catalyst Pharmaceuticals a dividend king?
Catalyst Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Catalyst Pharmaceuticals a dividend stock?
No, Catalyst Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Catalyst Pharmaceuticals stocks?
To buy Catalyst Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Catalyst Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.